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ABSTRACT 27 
Mature cystic teratomas (MCT) are common in women of all ages however malignant 28 
transformation within them is rare and difficult to diagnosis preoperatively.  29 
Primary melanoma of the ovary is exceptionally rare and only occurs in relation to a 30 
teratoma where it can originate from sporadic somatic mutagenesis within epidermal 31 
junctional melanocytes, through malignant transformation of a benign naevus formed 32 
within the MCT or from other well differentiated pigment containing structures such as the 33 
uvea.  34 
We present a case of primary malignant melanoma arising within a mature cystic teratoma 35 
in a young patient, who ultimately developed widespread metastasis necessitating systemic 36 
therapy. Our case highlights the role of molecular medicine not only in forming an 37 
understanding the origin of the melanoma, but also guiding targeted systemic therapies. 38 
Alongside the case we present a review of the literature describing the incidence of 39 
molecular aberrations within melanoma as well as the established and emerging techniques 40 
and cytotoxic agents for malignant melanoma.  41 
 42 
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INTRODUCTION 44 
Ovarian teratomas are common germ cell neoplasms and all contain mature or immature 45 
pluripotent cells arising from one or more dermal layers. Mature ovarian cystic teratomas 46 
(MCT) are the most common benign tumours found in women of all ages and are composed 47 
of mature histologic structures from at least two of the three germ layers: ectoderm, 48 
mesoderm and endoderm. They classically contain well differentiated tissue types, giving 49 
them a characteristic appearance.  50 
Malignant transformation within MCT is rare with an incidence of 0.6 - 2%. Of these, 51 
squamous cell carcinomas are the most common accounting for 80% of cases [1]. Ovarian 52 
malignant melanoma was first described in 1901 [2] with most reports being only of single 53 
cases [1, 3-8].  Pre-operative diagnosis of malignant transformation within MCTs is difficult 54 
with radiological detection of solid components being the only non-specific indicator. 55 
Additionally, encountering a melanoma in the ovary presents a particular diagnostic 56 
dilemma given the challenges in differentiating primary disease from secondary 57 
metastasises, taking into account the high degree of mimicry seen [9].  58 
We report a case of malignant ovarian melanoma arising within an MCT treated initially with 59 
fertility preservation surgery. We herein present this case with detailed 60 
immunohistochemistry and genetic profiling alongside a brief literature review. 61 
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CASE REPORT 64 
A 39-year-old nulliparous woman presented with sudden onset abdominal pain. Ultrasound 65 
examination demonstrated a septated left adnexal cyst, measuring 130 x 60 x 100 mm. With 66 
clinical suspicion of ovarian torsion she underwent emergency laparoscopic left ovarian 67 
cystectomy in the secondary care unit. Intraoperatively there was evidence of preoperative 68 
cyst rupture but no evidence of surface or extraovarian disease.  69 
The disrupted cystectomy specimen contained semi-solid material with enmeshed hair. Two 70 
solid areas were preferentially sampled and initial review suggested a torted mature cystic 71 
teratoma composed of skin, lamellar bone and fibrofatty tissue. In keeping with rupture 72 
there was a florid foreign body giant cell reaction to broken hair shafts. An area of small 73 
round blue cells was observed raising the possibility of lymphoma or an immature Sertoli 74 
Leydig cell tumour, and this prompted referral to the tertiary pathology centre. Further 75 
systematic sampling of the surgical material demonstrated no dysplasia or increase in 76 
melanocytes in the squamous lined epithelium. Towards the deep dermis and subcutis, and 77 
involving fibroconnective tissue elsewhere, was a small round blue cell tumour arranged in a 78 
nested pattern. In areas the tumour was composed of larger epithelioid cells with moderate 79 
eosinophilic cytoplasm, eccentric nuclei and irregular nuclear outlines, coarse chromatin 80 
and occasional intranuclear inclusions. Admixed with the larger cells there were diffuse 81 
sheets of relatively monomorphic small blue cells with increased cellular density around 82 
vascular structures and a hint of nesting in areas. They possessed basophilic small round, 83 
and in places irregular, nuclei with condensed chromatin, Figure 1. Mitoses were present 84 
but not brisk. Brown granular pigment was seen, positive for Fontana Masson stain (Figure 85 
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2A) and negative for Perls stain for iron, confirming it to be melanin pigment. Due to the 86 
fragmented and haemorrhagic nature of the specimen, architecture and relationship of the 87 
tumour to the skin and background benign structures was difficult to assess but there was 88 
no evidence of an intraepidermal or junctional melanocytic component.  89 
Immunohistochemistry demonstrated strong diffuse positivity for S100 (Figure 2B), Melan A 90 
(Figure 2C), vimentin, and NSE. The tumour showed weak patchy positivity for 91 
synaptophysin and CD117.  Ki67 proliferation fraction was variable with 5% proliferative 92 
activity in the larger cells with organoid areas and approximately up to 20-30% in the diffuse 93 
small cell areas. A wild type p53 staining pattern was seen throughout.  94 
Consideration of the morphology alongside the immunoprofile favoured a diagnosis of 95 
malignant melanoma arising in a mature cystic teratoma.   96 
Post-operative cross-sectional imaging demonstrated no lymphadenopathy or extraovarian 97 
disease and a full clinical Dermatology review excluded a primary cutaneous source. 98 
Following regional Melanoma multidisciplinary (MDT) review the patient opted to undergo 99 
fertility-sparing completion staging surgery with left salpingo-oophorectomy, bilateral pelvic 100 
and para-aortic node dissection, omentectomy and peritoneal washings. Peritoneal fluid 101 
cytology demonstrated cells suspicious of melanoma and histology confirmed malignant 102 
melanoma, similar in morphology and immunoprofile to that of the cystectomy specimen, 103 
present in the stroma, blood vessels and serosal surfaces of the ipsilateral fallopian tube and 104 
residual ovarian tissue. The tumour infiltrated the tissues in subtle linear arrays without 105 
eliciting any inflammatory reaction and without distorting background structures. All other 106 
specimens were negative with an assigned FIGO Stage of 2A [10].  107 
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Further whole body nuclear imaging excluded metastasis and the patient underwent 108 
definitive surgical excision with hysterectomy, right salpingo-oopherectomy and biopsies of 109 
bladder peritoneum and pelvic side wall, noted to be newly pigmented at the time of 110 
surgery. Histology demonstrated malignant melanoma within the contralateral ovary and 111 
peritoneal biopsies. 112 
DNA extracted from the primary FFPE tissue underwent mutational testing demonstrating 113 
wild type BRAF and NRAS with further testing demonstrating microsatellite stability but a 114 
loss of PTEN with deletions on exons 1 and 2.  115 
Six weeks after definitive surgery repeat radiological investigations demonstrated lung, liver 116 
parenchymal and bone metastases, as well as probable peritoneal disease. The patient 117 
received four cycles of combination immunotherapy with ipilimumab (monoclonal antibody 118 
to cytotoxic T-lymphocyte associated antigen 4 [CTLA-4]) and nivolumab (monoclonal 119 
antibody to programmed death 1 [PD-1]). One cycle of maintenance nivolumab was also 120 
given but follow-up cross-sectional imaging demonstrated progressive disease. 121 
Immunotherapy was consequently stopped and second-line treatment with dacarbazine 122 
commenced. She received three cycles and further widespread disease progression was 123 
evident at subsequent radiological assessment.  124 
Best supportive care was provided as she continued to deteriorate and she died 14 months 125 
following her initial emergency presentation.  126 
 127 
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DISCUSSION 128 
Primary ovarian malignant melanomas are exceptionally rare and as the ovary does not 129 
contain melanocytes, can only arise as part of a teratoid lesion. The frequency of the precise 130 
site of origin of ovarian melanomas within MCT is not known. The current case supports a 131 
diagnosis of primary melanoma in line with Cronje and Woodruff’s established diagnostic 132 
criteria which included: 1) absence of another primary melanoma; 2) unilateral ovarian 133 
tumour with an associated teratoid element; 3) correlation of clinical findings with those in 134 
the literature; and 4) demonstration of melanocytic junctional activity (although not 135 
mandatory for diagnosis) [11]. This case highlights a few areas of particular interest.  136 
Malignant melanomas typically arise de novo from the dermal-epidermal junction, however 137 
in this case there was no intraepidermal or junctional activity. It is therefore possible that 138 
this lesion originated either within a benign nevus or from another pigment-containing 139 
component of the MCT, for example the uveal epithelium. Retrospective review of the 140 
original cystectomy material revealed that the lesion was seen to be in close association 141 
with structures with ocular differentiation, (Figure 3A/B). The pattern of dissemination seen 142 
with the described case is in keeping with this site of origin. Uveal melanomas show a high 143 
rate of haematogenous metastasis with a propensity for liver [12], and due to lack of 144 
lymphatic drainage in the uvea, they do not spread to regional lymph nodes, in keeping with 145 
the negative nodes and disseminated disease seen in our case. This site of origin is further 146 
supported by the molecular profile of the tumour with literature reporting universal 147 
wildtype BRAF status of uveal melanomas [13].  Furthermore, loss of the tumour‐suppressor 148 
gene PTEN, has been shown to be prevalent in uveal melanoma with loss of cytoplasmic 149 
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PTEN expression negatively associated with disease free survival [14]. Mitsutaku et al 150 
describe a case of malignant melanoma arising within a MCT which was BRAF WT and PDL-1 151 
negative in whom there was no response to immune checkpoint inhibitors [15]. 152 
Furthermore, Tate et al describe another case of ovarian malignant melanoma found to be 153 
BRAF WT with loss of homology (LOH) of PTEN. Following paired mutational analysis of the 154 
benign MCT from which it arose they infer that LOH of PTEN may be a molecular alteration 155 
of the MCT with a further KIT mutation, found in the melanoma, acting as a promotional 156 
event associated with oncogenesis [16]. The lack of response to immunotherapy in the 157 
described case would also be in keeping with uveal origin, as it is known the uveal 158 
melanomas are generally not responsive to immune check-point inhibitors.  159 
Cancer of the ovary carries the highest mortality of all gynaecological malignancies and 160 
additionally melanomas arising in unusual sites are accepted to be associated with a poor 161 
prognosis. Specifically, in a collective series of 31 cases of primary ovarian melanoma, 162 
McNeilage et al reported that 43% of patients died of disease within 18 months of diagnosis 163 
[6]. Five of these patients received adjuvant platinum-based chemotherapy with only one 164 
patient receiving platinum combined with immunotherapy.  165 
In line with the management of epithelial ovarian cancer, surgery has historically formed the 166 
cornerstone of treatment of ovarian melanoma [4], and it is often necessary for an accurate 167 
diagnosis to be reached. Published literature demonstrates that the pattern of spread of 168 
primary ovarian melanoma (uveal or cutaneous origin) can replicate that of epithelial 169 
ovarian cancer but, in contrast to epithelial ovarian cancer, metastases more frequently 170 
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occur through lymphatic and haematogenous routes, giving rise to distant metastases in 171 
lymph nodes, lung, liver and bone.  172 
The combination of surgical cytoreduction and systemic therapy may confer a significant 173 
benefit in this rare disease but the role of adjuvant treatment is not established. 174 
Until a few years ago, melanoma patients had few effective systemic treatment options and 175 
historically, response rates to conventional chemotherapy and interleukin-2 or interferon-176 
gamma, have been low at only 5–19% [17]. New therapeutic options include treatments 177 
targeted to genetic mutations within tumours as well as immune modulators. 178 
Approximately 35-50% of all cutaneous melanomas harbour a BRAF gene mutation [18], 179 
resulting in a distinct phenotype, and the use of selective inhibitors of BRAF kinase alone 180 
[19] or in combination with inhibitors of the downstream MEK kinase has resulted in 181 
dramatic improvements in survival [20]. Patients with BRAF WT tumour may however 182 
experience paradoxical stimulation of the MAPK pathway resulting in tumour promotion if 183 
treated with a BRAF inhibitor [21] thus making molecular testing for BRAF mutations a 184 
priority to determine the course of therapy. More recently immunotherapy with immune 185 
check point inhibitors has also demonstrated a significant improvement in survival for 186 
patients with BRAF mutant and wild type cutaneous melanoma [22], however response 187 
rates are significantly lower in uveal or mucosal melanomas. 188 
The PTEN tumour suppressor gene is one of the most frequently inactivated tumour 189 
suppressor genes in sporadic cancers with an estimated frequency of 7.3% and 15.2% in 190 
primary and metastatic melanomas [23]. PTEN modulates protein synthesis, cell cycle, 191 
migration, growth, DNA repair, and survival signalling by regulating phosphoinositide-3-192 
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kinase (PI3K) and the protein-Ser/Thr kinase (AKT) signalling pathway [24]. Loss of function 193 
mutations in PTEN occur in only a fraction of PTEN-deficient tumours hence the need to 194 
determine PTEN status by protein quantification and DNA sequencing [25]. Previous studies 195 
have shown frequent co-occurrence of BRAF mutations and PTEN mutations or 196 
deletions [26]. However, in the TCGA’s proposed classification of melanoma into four 197 
genomic subtypes (BRAF, RAS, NF1 and triple WT), a higher frequency of amplifications and 198 
overexpression of AKT3 is seen in RAS, NF1, and Triple-WT melanomas, which may support 199 
the use of combination MEK and PI(3)K/AKT/mTOR pathway inhibitors in such subtypes 200 
[18].  201 
This case report is an example of an aggressive malignant melanoma within an MCT, 202 
showing resistance to first- and second-line therapies. In view of pathological features, we 203 
have found lack of mitotic figures and low proliferation fraction can be misleading in the 204 
diagnosis of malignant melanoma. In relation to immunohistochemical stains, it is also 205 
important to note the synaptophysin and CD117 positivity in this case. This is an interesting 206 
finding, as it may be seen in immature neural components of a teratoma. Alongside this, 207 
molecular testing offers insight into the site of origin as well as provide vital information to 208 
determine therapeutic paths.  209 
 210 
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FIGURE LEGENDS 211 
Figure 1. H and E of initial cystectomy specimen. Nests of melanoma cells deep in the subcu‐212 
tis with no connection to overlying surface squamous epithelium or adnexal structures. X1 213 
magnification. 214 
Figure 2. . Immunohistochemistry of initial cystectomy specimen. Five micron‐thick paraffin 215 
sections of initial cystectomy specimen were cut onto slides, deparaffinised in xylene and re‐216 
hydrated in descending gradients of thanol. Endogenous peroxidase and non‐specific bind‐217 
ing were blocked before addition of primary antibodies on an automated Ventana stainer:  218 
(A) Fontana‐Masson melanin stain, where the melanin granules reduce ammonia‐silver 219 
nitrate and turn black.  220 
(B) S100 (1:500). Diffuse and dense cytoplasmic and nuclear staining of S100 was seen 221 
denoting proliferation of melanoma cells. Strongly positive cells are seen inter‐222 
spersed throughout the tissue sample;  223 
(C) Melan A stain (1:12.5), a specific melanocyte lineage marker. Diffuse cytoplasmic 224 
staining is seen. 225 
Figure 3. H and E of initial cystectomy specimen. Basal layer of the double layered uveal epi‐226 
thelium giving rise to  small melanoma cells, invading the richly vascularised connective tis‐227 
sue below.  X10 magnification.  228 
(A) foci of brown melanin pigment signifying melanoma cells arising from conjuncti‐229 
val/uveal tissue.   230 
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(B) Melanoma cells abutting conjunctival epithelium. Uveal epithelium with melanoma 231 
cells arising from the basal layer of the left edge of the image undermining adjacent 232 
epithelium and invading underlying connective tissue. 233 
 234 
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